Raising the Standard of Care with Accuplex Testing
In this one hour webinar, you will learn more about Antech's Accuplex which is a reference laboratory test used to screen for Lyme disease, heartworm, Ehrlichia, and Anaplasma.
Lyme disease detection on the Accuplex platform now also screens for antibodies to C6. The C6 peptide exists in the invariable region (IR6) of the VIsE surface lipoprotein of Borrelia burgdorferi and is only expressed following natural infection or exposure of a host. Therefore, a positive C6 result will not be reported from cross-reactivity with vaccinal antibodies. Lyme disease results will be reported as either positive or negative for the detection of antibodies against C6.
When it comes to screening your patients for Heartworm, Lyme disease, Ehrlichia, and Anaplasma, the Accuplex test offers high quality testing at an affordable price.
Led by: Dr. Jennifer Lopez
DVM, MBA Antech Professional Services
Improving Outcomes for Feline CKD with Predictive Diagnostics
In this one hour webinar, learn how Antech's predictive diagnostic, RenalTech®, can help drive better outcomes for feline patients. Powered by artificial intelligence, RenalTech uses common serum and urine diagnostics to predict whether a cat will develop chronic kidney disease in the next two years—with greater than 95% accuracy!
The biggest advantage is this diagnostic tool uses common blood and urine tests that you already run routinely on your feline patients, combined with the pet’s age.
Led by: Dr. Lindsay M. VanHusan
DVM, Antech Professional Services
Led by: Dr. Christian Leutenegger DrMedVet, BSc, PhD, FVH; Director Molecular Diagnostics R&D
Dr. Jennifer Lopez DVM MBA,Professional Service Veterinarian
Using Molecular Diagnostics to Detect Canine Bladder and Prostate Cancer
In this one hour webinar, you will learn more on detecting both prostate and bladder cancer in canines utilizing the CADET® BRAF urine test. This test allows for early diagnosis in clinical cases with recurrent, complicated, or antibiotic-resistant urinary tract infections presenting with hematuria without ultrasonographic evidence of a bladder mass.
Dr. Sue Ettinger will share how this new cutting edge test will simplify diagnosing these rare cancers in the hope of achieving better health outcomes.
Led by: Dr. Sue Ettinger
DVM, DACVIM (Oncology)
FIRSTract™: The new best practice in rapid urine culture
FIRSTract™ is the first reference laboratory automated assay for quick urine culture, delivering accurate and reliable results within hours for a more streamlined first step diagnosis for your patients. Plus, FIRSTract’s innovative methodology represents a better track forward for antimicrobial stewardship—one that can significantly reduce the amount of antibiotics being prescribed unnecessarily by providing a faster way of detecting if a bacterial infection is present. In this 50 minute webinar Dr. Rita Hanel shares her insight on the value of FIRSTract including real-life case studies.